Loading
A phase 1/2 trial of Sacituzumab tirumotecan in ovarian cancer and non-small-cell lung cancer, run by Klus Pharma Inc., active and no longer recruiting.
Phase I-II, FIH, TROP2 ADC, Advanced Unresectable/Metastatic Solid Tumors, Refractory to Standard Therapies (KL264-01) is a phase 1/2 interventional study registered as NCT04152499 by Klus Pharma Inc., with 1410 participants enrolled, started 2020-02-28 and due to reach its primary completion in 2026-12-31. Interventions recorded: SKB264. Conditions listed: Epithelial Ovarian Cancer, Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Urothelial Carcinoma. No results are recorded here; the registry entry is the source.
Shares Sichuan Kelun-Biotech, Sacituzumab tirumotecan, Topoisomerase-I inhibitors (and ADC payloads), Antibody-drug conjugate (ADC).
Shares Sichuan Kelun-Biotech, Sacituzumab tirumotecan, Topoisomerase-I inhibitors (and ADC payloads), Antibody-drug conjugate (ADC).
Shares Sacituzumab tirumotecan, Topoisomerase-I inhibitors (and ADC payloads), Antibody-drug conjugate (ADC), Small-cell lung cancer.
Shares Sichuan Kelun-Biotech, Sacituzumab tirumotecan, Small-cell lung cancer, Non-small-cell lung cancer.
Shares Sichuan Kelun-Biotech, Sacituzumab tirumotecan, Small-cell lung cancer, Non-small-cell lung cancer.
Shares Sichuan Kelun-Biotech, Sacituzumab tirumotecan, Small-cell lung cancer, Non-small-cell lung cancer.
Shares Sacituzumab tirumotecan, Topoisomerase-I inhibitors (and ADC payloads), Antibody-drug conjugate (ADC), Small-cell lung cancer.
Shares Sacituzumab tirumotecan, Topoisomerase-I inhibitors (and ADC payloads), Antibody-drug conjugate (ADC), Small-cell lung cancer.